Showing 4 posts of 4 posts found.


AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD

May 30, 2023
Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris

AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 complement inhibitor for the prevention …

AstraZeneca’s Ultomiris approved in EU for adults firm NMOSD

May 11, 2023
Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris, neurology

AstraZeneca has announced the approval of Ultomiris (ravulizumab) in the European Union (EU) for the treatment of adult patients with …


FDA approves Alexion’s Ultomiris in atypical haemolytic uremic syndrome for adults and children

October 21, 2019
Sales and Marketing Alexion, FDA, Ultomiris, pharma, rare disease

The FDA has moved to expand the existing label for Alexion’s Ultomiris (ravulizumab-cwvz) to include the treatment of atypical haemolytic …


European approval for Alexion’s Ultomiris in rare blood disease

July 4, 2019
Sales and Marketing Alexion, Europe, Ultomiris, paroxysmal nocturnal haemoglobinuria

Alexion has received marketing authorisation from the European Commission for its long-acting C5 complement inhibitor Ultomiris (ravulizumab) in the treatment …

Latest content